Panel discussion: Recent advances in early and advanced stage non-small-cell lung cancer (NSCLC) presented at ESMO 2023

In this engaging panel discussion, renowned experts in non-small-cell lung cancer, Dr. Luis Paz-Ares, Prof. Solange Peters and Dr. Marina Garassino provide their insights on the latest findings from the following pivotal phase III trials: ALINA, CheckMate-77T, LIBRETTO-431, and MARIPOSA-1 and -2 presented at ESMO 2023.

Presentation date: Tuesday 24th October 2023

Speakers

• Dr. Luis Paz-Ares
  University Hospital October 12, Madrid, Spain. Read more
• Prof. Solange Peters 
  University Hospital of Lausanne, Lausanne, Switzerland. Read more
• Dr. Marina Garassino 
  University of Chicago, Illinois, USA. Read more

Speaker disclosures

Dr. Luis Paz-Ares

• Speaker fees: AZ, Beigene, BMS, Daichii, Lilly, Medscape, MSD, PER, Pharmamar, Roche.
• Board member: Altum sequencing, Genomica, Stab Therapeutics.
• Advisory boards: Amgen, AZ, Bayer, Beigene, BMS, Daichii, GSK, Janssen, Lilly, Medscape, Merck Serono, Mirati, MSD, Novartis, PER, Pfizer, Pharmamar, Roche, Sanofi, Takeda.
• Other: Altum sequencing, Genomica, ONCOSUR.
• Personal: Altum sequencing, Amgen, AZ, Bayer, Beigene, BMS, Daichii, Genomica, GSK, Janssen, Lilly, Medscape, Merck Serono, Mirati, MSD, Novartis, PER, Pfizer, Pharmamar, Roche, Sanofi, Takeda, Stab Therapeutics, Amgen.
• Institutional: Alkermes, AZ, BMS, Daiichi Sankyo, Janssen-cilag international NV, Lilly, Merck Sharp & Dohme corp, Novartis, Pfizer, Pharmamar, Roche, Sanofi, Takeda, Tesaro.
• Coordinating PI: Alkermes, Amgen, AZ, BMS, Daiichi Sankyo, Janssen-cilag international NV, Lilly, Merck Sharp & Dohme corp, Novartis, Pfizer, Pharmamar, Roche, Sanofi, Takeda, Tesaro.
• Financial interest: Alkermes, Amgen, AZ, BMS, Daiichi Sankyo, Janssen-cilag international NV, Lilly, Merck Sharp & Dohme corp, Novartis, Pfizer, Pharmamar, Roche, Sanofi, Takeda, Tesaro.

Prof. Solange Peters

• Consultation / Advisory role: AbbVie, Amgen, Arcus, AstraZeneca, Bayer, Beigene, BerGenBio, Biocartis, BioInvent, Blueprint Medicines, Boehringer Ingelheim, Bristol-Myers Squibb, Clovis, Daiichi Sankyo, Debiopharm, Eli Lilly, F-Star, Fishawack, Foundation Medicine, Genzyme, Gilead, GSK, Hutchmed, Illumina, Incyte, Ipsen, iTeos, Janssen, Merck Sharp and Dohme, Merck Serono, Merrimack, Mirati, Nykode Therapeutics, Novartis, Novocure, Pharma Mar, Promontory Therapeutics, Pfizer, Regeneron, Roche/Genentech, Sanofi, Seattle Genetics, Takeda.
• Board of Director position: Galenica.
• Talk in a company’s organized public event: AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Foundation Medicine, GSK, Illumina, Ipsen, Merck Sharp and Dohme, Mirati, Novartis, Pfizer, Roche/Genentech, Sanofi, Takeda.
• Receipt of grants/research supports: Principal investigator in trials (institutional financial support for clinical trials) sponsored by Amgen, Arcus, AstraZeneca, Beigene, Bristol-Myers Squibb, GSK, iTeos, Merck Sharp and Dohme, Mirati, Pharma Mar, Promontory Therapeutics, Roche/Genentech, Seattle Genetics.

Dr. Marina Garassino

• Honoraria: MSD Oncology, AstraZeneca/MedImmune, GlaxoSmithKline, Takeda, Roche, Bristol-Myers Squibb, Daiichi Sankyo/AstraZeneca, Regeneron, Pfizer, Blueprint Pharmaceutic, Novartis, Sanofi/Aventis, Medscape.
• Consultancy or Advisory role: Bristol-Myers Squibb, MSD, AstraZeneca, Novartis, Takeda, Roche, Sanofi-Aventis, Celgene, Daiichi Sankyo, Pfizer, Seattle Genetics, Eli Lilly, GlaxoSmithKline, Bayer Healthcare Pharmaceuticals, Blueprint Medicines, Janssen, Regeneron, Bayer, Abbvie, Mirati, Merck, Boehringer Ingelheim, Blueprint Medicines, Abion.
• Speakers' Bureau: AstraZeneca, MSD Oncology, Merck, Mirati, Daiichi Sankyo/AstraZeneca.
• Research Funding: Bristol-Myers Squibb, MSD, Roche/Genentech, AstraZeneca/MedImmune, AstraZeneca, Pfizer, GlaxoSmithKline, Novartis, Merck, Incyte, Takeda, Spectrum Pharmaceuticals, Blueprint Medicines, Eli Lilly, AstraZeneca, Ipsen, Janssen, Exelixis, MedImmune, Sanofi, Amgen.
• Travel, Accommodations, Expenses: Pfizer, Roche, AstraZeneca.

Financial disclosure

This content is intended only for healthcare providers and was made possible by educational funding provided by F. Hoffmann-La Roche Ltd.

Disclaimer

Any information provided and opinions expressed do not necessarily reflect the views of Springer Medizin GmbH. Springer Medizin GmbH and its employees, agents and subcontractors are not responsible or in any way liable for the currency of the information, for any errors, omissions or inaccuracies, or for any consequences arising therefrom. Inclusion or exclusion of any product does not imply its use is either advocated or rejected. Use of trade names is for product identification only and does not imply endorsement. Please consult the latest prescribing information from the manufacturer before issuing prescriptions for any products mentioned.